Epic Sciences Awarded a Phase II SBIR Contract From National Cancer Institute/National Institutes of Health (NIH) to Develop a Lung Cancer Diagnostic Blood Test
Published: Jan 24, 2013
SAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc., (“Epic”), a private biotech company that develops breakthrough cancer diagnostics, announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI) and the National Institutes of Health (NIH). The contract will fund the further development of an assay to identify and characterize circulating tumor cells (CTCs) in lung cancer patients. The results of this contract are expected to provide a basis for the development of new cancer diagnostic products.